Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report) has received an average rating of “Buy” from the seven research firms that are covering the company, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy rating. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $22.00.
OLMA has been the topic of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Olema Pharmaceuticals in a research report on Tuesday, June 4th. The Goldman Sachs Group initiated coverage on Olema Pharmaceuticals in a research report on Tuesday, April 2nd. They set a “buy” rating and a $24.00 price target on the stock.
Check Out Our Latest Stock Report on Olema Pharmaceuticals
Insiders Place Their Bets
Hedge Funds Weigh In On Olema Pharmaceuticals
Several institutional investors have recently modified their holdings of OLMA. Public Employees Retirement System of Ohio bought a new position in shares of Olema Pharmaceuticals during the 3rd quarter valued at about $35,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Olema Pharmaceuticals during the 4th quarter valued at about $89,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Olema Pharmaceuticals during the 4th quarter valued at about $130,000. Entropy Technologies LP purchased a new stake in Olema Pharmaceuticals during the 1st quarter valued at about $161,000. Finally, EntryPoint Capital LLC grew its position in Olema Pharmaceuticals by 949.9% during the 1st quarter. EntryPoint Capital LLC now owns 14,530 shares of the company’s stock worth $164,000 after acquiring an additional 13,146 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors.
Olema Pharmaceuticals Trading Down 1.6 %
OLMA stock opened at $15.19 on Thursday. Olema Pharmaceuticals has a 1-year low of $7.78 and a 1-year high of $17.79. The stock’s fifty day simple moving average is $12.08 and its two-hundred day simple moving average is $12.01. The stock has a market cap of $849.58 million, a P/E ratio of -7.52 and a beta of 2.06.
Olema Pharmaceuticals (NASDAQ:OLMA – Get Free Report) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.03). As a group, analysts forecast that Olema Pharmaceuticals will post -2.3 earnings per share for the current fiscal year.
About Olema Pharmaceuticals
Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.
Featured Articles
- Five stocks we like better than Olema Pharmaceuticals
- 3 REITs to Buy and Hold for the Long Term
- Survey: Top 175 Fittest Retirement Locations in America
- Dividend Payout Ratio Calculator
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- Profitably Trade Stocks at 52-Week Highs
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for Olema Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olema Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.